283 related articles for article (PubMed ID: 37682937)
1. Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies.
Yousif FA; Alzain AA; Alraih AM; Ibraheem W
PLoS One; 2023; 18(9):e0291256. PubMed ID: 37682937
[TBL] [Abstract][Full Text] [Related]
2. Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme.
Adon T; Shanmugarajan D; Ather H; Ansari SMA; Hani U; Madhunapantula SV; Honnavalli YK
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985460
[TBL] [Abstract][Full Text] [Related]
3. Dual aromatase-steroid sulfatase inhibitors (DASI's) for the treatment of breast cancer: a structure guided ligand based designing approach.
Singh Y; Jaswal S; Singh S; Verma SK; Thareja S
J Biomol Struct Dyn; 2023 Dec; 41(20):10604-10626. PubMed ID: 36510679
[TBL] [Abstract][Full Text] [Related]
4.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
5. A Search for Cyclin-Dependent Kinase 4/6 Inhibitors by Pharmacophore-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations.
Susanti NMP; Damayanti S; Kartasasmita RE; Tjahjono DH
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948218
[TBL] [Abstract][Full Text] [Related]
6. Repositioning of experimentally validated anti-breast cancer peptides to target FAK-PAX complex to halt the breast cancer progression: a biomolecular simulation approach.
Khan A; Shan S; Toor TF; Suleman M; Wang Y; Zhou J; Wei DQ
Mol Divers; 2023 Apr; 27(2):603-618. PubMed ID: 35635599
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer.
Awasthi M; Singh S; Pandey VP; Dwivedi UN
J Biomol Struct Dyn; 2015; 33(4):804-19. PubMed ID: 24702656
[TBL] [Abstract][Full Text] [Related]
8. Controlling cell proliferation by targeting cyclin-dependent kinase 6 using drug repurposing approach.
Madhana Priya N; Balasundaram A; Sidharth Kumar N; Udhaya Kumar S; Thirumal Kumar D; Magesh R; Zayed H; George Priya Doss C
Adv Protein Chem Struct Biol; 2023; 135():97-124. PubMed ID: 37061342
[TBL] [Abstract][Full Text] [Related]
9. Design of Novel Letrozole Analogues Targeting Aromatase for Breast Cancer: Molecular Docking, Molecular Dynamics, and Theoretical Studies on Gold Nanoparticles.
Edris A; Abdelrahman M; Osman W; Sherif AE; Ashour A; Garelnabi EAE; Ibrahim SRM; Bafail R; Samman WA; Ghazawi KF; Mohamed GA; Alzain AA
Metabolites; 2023 Apr; 13(5):. PubMed ID: 37233624
[TBL] [Abstract][Full Text] [Related]
10.
Maruthanila VL; Elancheran R; Mirunalini S
Curr Comput Aided Drug Des; 2022; 18(3):196-212. PubMed ID: 35598239
[TBL] [Abstract][Full Text] [Related]
11. Unveiling the multitargeted repurposing potential of taxifolin (dihydroquercetin) in cervical cancer: an extensive MM\GBSA-based screening, and MD simulation study.
Almasoudi HH; Hakami MA; Alhazmi AY; Makkawi M; Alasmari S; Alghamdi YS; Mashraqi MM
Med Oncol; 2023 Jul; 40(8):218. PubMed ID: 37394519
[TBL] [Abstract][Full Text] [Related]
12. Exploring Potential Non-steroidal Aromatase Inhibitors for Therapeutic Application against Estrogen-dependent Breast Cancer.
Pandey K; Bharat Lokhande K; Saha A; Goja A; Swamy KV; Nagar S
Curr Comput Aided Drug Des; 2023; 19(4):243-257. PubMed ID: 36644872
[TBL] [Abstract][Full Text] [Related]
13. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
Tripathi SK; Muttineni R; Singh SK
J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
[TBL] [Abstract][Full Text] [Related]
14. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
15. Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment.
Gobbi S; Martini S; Rozza R; Spinello A; Caciolla J; Rampa A; Belluti F; Zaffaroni N; Magistrato A; Bisi A
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049810
[TBL] [Abstract][Full Text] [Related]
16. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
17. Computational exploration of allosteric inhibitors targeting CDK4/CDK6 proteins: a promising approach for multi-target drug development.
Khan M; Singh K; Khan S; Ahmad B; Khushal A; Yingning S
J Biomol Struct Dyn; 2024 Jan; ():1-19. PubMed ID: 38174658
[TBL] [Abstract][Full Text] [Related]
18. Targeting protein tyrosine phosphatase to unravel possible inhibitors for Streptococcus pneumoniae using molecular docking, molecular dynamics simulations coupled with free energy calculations.
Zaman Z; Khan S; Nouroz F; Farooq U; Urooj A
Life Sci; 2021 Jan; 264():118621. PubMed ID: 33164832
[TBL] [Abstract][Full Text] [Related]
19. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
20. Computational investigation of
Yousaf MA; Anwer SA; Basheera S; Sivanandan S
J Biomol Struct Dyn; 2024; 42(4):1901-1923. PubMed ID: 37154824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
